Xbrane Biopharma AB has carried out an oversubscribed primary issuance of shares of approximately SEK 240 million through an accelerated bookbuilding procedure.
Xbrane develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm.
Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to Xbrane with a capital markets team consisting of Joakim Falkner, Johanna Flink, Carl Isaksson and Simon Olofsson.
